ICH Q14 Promotes Industrial Concentration Of Urinary API Sector

The implementation of ICH Q14 has raised R&D and equipment upgrading costs for small and medium-sized urinary HCG, HMG and urokinase manufacturers. Leading domestic enterprises have completed quality system iteration, while non-compliant small players are gradually exiting the market, and the industry concentration is continuously improved.